
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is in a strong financial position with significant milestones in their pipeline, including ongoing Phase 3 trials for Ibsrela and Xphozah, and a successful patient assistance program. With a patent in place until 2042, the company has a stable foundation for long-term growth and expansion opportunities in the treatment of CIC and other conditions. As they continue to progress in their clinical trials and expand their market reach, Ardelyx has the potential for sustained revenue growth and higher shareholder value.
Bears say
Ardelyx is facing challenges with its increasing operating expenses, low adherence to Xphozah due to high pill burden, and potential competition in the CIC market, which could impact the company's top-line growth and future adoption of its products. The company must successfully execute the ongoing Phase 3 ACCEL trial and demonstrate meaningful benefits for CIC patients to maintain growth as per its revenue guidance targets. Additionally, the company must differentiate its NHE3 inhibitor IBSRELA from other approved secretagogues in the market and gain broader labeling and familiarity among prescribers to ensure future adoption and treatment of both IBS-C and CIC patients.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares